Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Epinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.79 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.79 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.79 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.79 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.79 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.79 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.79 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 7/20 | 1.00 |
| ▸ | TSHR | P16473 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL29587492 | 1.00 | KDM4E (1.00) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| L-Adrenaline SCHEMBL20608410 | 1.00 | KDM4E (1.00) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Epinephrine SCHEMBL27968525 | 1.00 | KDM4E (1.00) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL40742 | 1.00 | KDM4E (1.00) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL4406973 | 1.00 | KDM4E (1.00) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| L-Adrenaline SCHEMBL26986346 | 1.00 | KDM4E (1.00) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Epinephrine SCHEMBL40741 | 1.00 | KDM4E (1.00) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Epinephrine SCHEMBL28412215 | 0.98 | KDM4E (0.97) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Racepinephrine SCHEMBL4066533 | 0.98 | KDM4E (0.97) | KDM4ETDP1MAPTADRB2HSD17B10 | |
| Epinephrine SCHEMBL7394380 | 0.91 | KDM4E (0.83) | KDM4ETDP1MAPTADRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3678643-B1 | SUBLINGUAL EPINEPHRINE TABLETS | pHase Pharmaceuticals LLC (US) | 2025-11-26 | — | — | EP | claimed |
| EP-3678643-B1 | SUBLINGUAL EPINEPHRINE TABLETS | pHase Pharmaceuticals LLC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250275983-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | Sydnexis, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250186251-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | Sydnexis, Inc. | 2025-06-12 | — | — | US | disclosed |
| US-12168017-B2 | D2O stabilized pharmaceutical formulations | Sydnexis, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12070466-B2 | D2O stabilized pharmaceutical formulations | Sydnexis, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-08-15 | — | — | US | disclosed |
| US-20230381016-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | Sydnexis, Inc. | 2023-11-30 | — | — | US | disclosed |
| US-11246843-B2 | Method for increasing plasma concentration of epinephrine in a subject having a condition responsive to epinephrine | NOVA SOUTHEASTERN UNIVERSITY (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186251-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | CHRM3, CHRM2, CHRM4 | ADRB2 9/4885ADRB1 8/4885ADRB3 19/4885 |
| US-12070466-B2 | D2O stabilized pharmaceutical formulations | AQP1, AQP3, CRYZ | ADRB2 1048/4885ADRB1 1041/4885ADRB3 776/4885 |
| US-12168017-B2 | D2O stabilized pharmaceutical formulations | AQP1, AQP3, CRYZ | ADRB2 1048/4885ADRB1 1041/4885ADRB3 776/4885 |
| US-20250275983-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | AQP1, AQP3, CRYZ | ADRB2 1048/4885ADRB1 1041/4885ADRB3 776/4885 |
| US-20240269156-A1 | DISULFIDE CONTAINING THERAPEUTICS | P4HB, PDIA5, PDIA4 | ADRB2 4663/4885ADRB1 4523/4885ADRB3 4413/4885 |
| US-20230381016-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | CHRM3, CHRM2, CHRM4 | ADRB2 9/4885ADRB1 8/4885ADRB3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.